Translated title of the contribution: Phase II study with vindesine (desacetyl-vinblastine-amide-sulfate) in advanced malignant diseases

A. Goldhirsch, M. Beer, R. W. Sonntag, L. Tschopp, F. Cavalli, H. J. Ryssel, K. W. Brunner

Research output: Contribution to journalArticlepeer-review


53 patients with advanced and measurable cancer were treated with vindesine in doses of 3 mg/m 2 (pretreated) and 4 mg/m 2 (non pretreated) i.v. once weekly. 48 patients are evaluable for response: of 14 patients with squamous cell carcinoma of the lung, 1 partial remission (PR), 1 minor response (MR) and 1 no change (NC) were observed. In 5 patients with large cell carcinoma of the lung: 1 NC. In 3 with adenocarcinoma of the lung: 1 MR. One patient with nasopharyngeal carcinoma had progressive disease. Stable disease was observed in a patient with carcinoma of the tongue and in a patient with adenocarcinoma of the esophagus. Four patients with colorectal carcinoma had progressive disease. One MR was observed in a patient with breast cancer, while all of the other 3 patients had progressive disease. One carcinoma of the penis was stable. One MR was observed in a patient with Hodgkin's disease. One PR was observed in a case with non-Hodgkin's lymphoma. A patient with acute leukemia had progressive disease. Among 9 patients with malignant melanoma, 3 had an MR and 1 patient had stable disease. A patient with fibrosarcoma had progressive disease. Observed toxicity included leukopenia, thrombocytopenia, anemia, paresthesias, constipation, jaw pain, nausea, stomatitis, alopecia, loss of taste, pruritus and skin rash, weakness and fatigue.

Translated title of the contributionPhase II study with vindesine (desacetyl-vinblastine-amide-sulfate) in advanced malignant diseases
Original languageGerman
Pages (from-to)1063-1067
Number of pages5
JournalSchweizerische Medizinische Wochenschrift
Issue number27-28
Publication statusPublished - 1980

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Phase II study with vindesine (desacetyl-vinblastine-amide-sulfate) in advanced malignant diseases'. Together they form a unique fingerprint.

Cite this